Gene signatures of drug resistance predict patient survival in colorectal cancer

Y. Zheng, J. Zhou, Y. Tong

Research output: Contribution to journalArticlepeer-review

52 Scopus citations


Different combinations of 5-fluorouracil (5-FU), oxaliplatin, irinotecan and other newly developed agents have been used to treat colorectal cancer. Despite the advent of new treatment regimens, the 5-year survival rate for metastatic colorectal cancer remains low (∼10%). Knowing the drug sensitivity of a given tumor for a particular agent could significantly impact decision making and treatment planning. Biomarkers are proven to be successful in characterizing patients into different response groups. Using survival prediction analysis, we have identified three independent gene signatures, which are associated with sensitivity of colorectal cancer cells to 5-FU, oxaliplatin or irinotecan. On the basis of the three gene signatures, three score systems were developed to stratify patients from sensitive to resistance. These score systems exhibited robustness in stratify patients in two independent clinical studies. Patients with high scores in all three drugs exhibited the lowest survival.

Original languageEnglish (US)
Pages (from-to)135-143
Number of pages9
JournalPharmacogenomics Journal
Issue number2
StatePublished - Apr 25 2015

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology


Dive into the research topics of 'Gene signatures of drug resistance predict patient survival in colorectal cancer'. Together they form a unique fingerprint.

Cite this